Skip to main content
. 2024 Apr 17;16(8):1529. doi: 10.3390/cancers16081529

Figure 2.

Figure 2

The proportion of pharmaceutical expenditure for antineoplastic drugs in the routine healthcare setting and in sponsor-supported clinical trials.